HER2/neu testing in primary colorectal carcinoma.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Anti-HER2/neu therapy is established for breast and gastric cancers.
• The role of HER2/neu in colorectal carcinoma remains controversial with conflicting data.
• Understanding HER2/neu pathways has led to new therapeutic agents beyond trastuzumab.

Purpose of the Study:

• To determine the prevalence of HER2/neu positivity in a large cohort of colorectal carcinoma patients.
• To correlate HER2/neu status with clinico-pathological features and patient survival.
• To evaluate the potential of HER2/neu as a therapeutic target in colorectal cancer.

Main Methods:

• Retrospective analysis of 1645 primary colorectal carcinoma cases.
• HER2/neu status testing according to current diagnostic recommendations.
• Correlation of HER2/neu positivity with UICC stage, lymph node metastases, and T-category.

Main Results:

• HER2/neu positivity was observed in 1.6% of colorectal carcinomas.
• HER2/neu positivity significantly correlated with higher UICC stages and lymph node metastases.
• In sigmoidal and rectal carcinomas, HER2/neu positivity was associated with T-category and advanced UICC stages.

Conclusions:

• HER2/neu testing is crucial using validated diagnostic methods and scoring systems.
• Despite low prevalence, HER2/neu testing is recommended for advanced, nodal-positive colorectal cancer.
• HER2/neu represents a potential therapeutic target for high-risk colorectal carcinoma patients.